Uloženo v:
| Hlavní autor: | |
|---|---|
| Médium: | Recurso digital |
| Jazyk: | |
| Vydáno: |
Zenodo
2025
|
| On-line přístup: | https://doi.org/10.5281/zenodo.16912649 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
Obsah:
- <p dir="ltr">Breast cancer can be positive for expression of a hormone receptor (ESR/PGR/AR) or a growth factor receptor (ERBB2). Disease recurrence following disease remission (relapse), resistance to endocrine therapy or otherwise inadequate long-term control of disease are challenges that limit effectiveness of existing drugs that treat luminal A and luminal B receptor disease. Here we utilized whole transcriptome technologies (5, 6) to measure total transcription in the primary tumors of humans with luminal A and luminal B breast cancer. We describe one member of a group of kinases up-regulated and differentially expressed in human luminal A breast cancer, PIK3R1, as a catalytically available enzyme and candidate therapeutic target for the adjunctive medical treatment of luminal A breast cancer. </p>